PSC
SRPT icon

Piper Sandler & Co’s Sarepta Therapeutics SRPT Stock Holding History

Piper Sandler & Co’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-2,500
Closed -$53K – 157
2014
Q3 		$53K Buy
+2,500
New +$56.4K 0.03% 109

Other funds holding SRPT

CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Piper Sandler & Co's SRPT Position: Q4 2014 in Review

Piper Sandler & Co sold out of Sarepta Therapeutics (SRPT) in Q4 2014, closing a stake of 2,500 shares — an estimated $53K sold.

Piper Sandler & Co first reported a position in SRPT in Q3 2014 and held it in 1 quarter. The position peaked at $53K in Q3 2014. 120 funds tracked by Wall St. Rank hold SRPT as of Q4 2014.

  • Piper Sandler & Co reported no remaining Sarepta Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Piper Sandler & Co sold 2,500 Sarepta Therapeutics shares in Q4 2014, an estimated $53K.
  • Piper Sandler & Co first reported a position in Sarepta Therapeutics in Q3 2014 and held it in 1 quarter.
  • Piper Sandler & Co's Sarepta Therapeutics position peaked at $53K in Q3 2014.
  • 120 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2014.

Based on Piper Sandler & Co's 13F filing for Q4 2014, filed 17 Feb 2015.